In
short, the Pfizer document (which was never supposed to see the light
of day but was disclosed as part of a FOIA suit) describes the adverse
effects from just the first three months of injections with the
company’s COVID vaccine:
158,000
adverse events, 1223 deaths. In a half-sane world, this would have been
more than enough to halt all injections and cancel the vaccine.
I’ve queried two attorneys. They both looked at the Pfizer document and state they believe it’s authentic.
The
appendix of the Pfizer document is the most astonishing section. It’s
beyond astonishing. It lists all the types of vaccine adverse events
Pfizer logged---again, in just three months of injections.
Page
after page after page after page of types of adverse events. Each type
of event cast in medical language, the language of the dead. The
proponents of this technical-ese speak, as it were, from beyond the
grave. They’re super-educated brainwashed zombies. It’s as if they’re
listing and counting abstractions in an academic board game.
The
abstractions raise no concerns. In the document, no one is waving red
flags. They’re all medical bean counters, keeping their books with
precision.
Make
no mistake, these are the people who are operating the levers of
society on a day-to-day basis, maiming and killing with a confident
attitude that indicates they are beyond reproach. The very notion of
reproach is foreign to them.
Civilization
is drowning. It’s drowning in a giant lake of TECHNIQUE. The uses to
which technique is put have become irrelevant. Just follow
procedure. Carry out assigned tasks. Pass along information. Report on
results. And then you will have achieved immunity from blame.
Or resist and rebel no matter what. These are the stakes. This is the war.
Get
ready. Buckle up. Logged by Pfizer, covering the first three months of
COVID vaccination, here is the corporation’s list of types of vaccine
adverse events, as published by Celia Farber:
* * *
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports
APPENDIX 1. LIST OF ADVERSE EVENTS OF SPECIAL INTEREST
1p36
deletion syndrome; 2-Hydroxyglutaric aciduria; 5'nucleotidase
increased; Acoustic neuritis; Acquired C1 inhibitor deficiency; Acquired
epidermolysis bullosa; Acquired epileptic aphasia; Acute cutaneous
lupus erythematosus; Acute disseminated encephalomyelitis; Acute
encephalitis with refractory, repetitive partial seizures; Acute febrile
neutrophilic dermatosis; Acute flaccid myelitis; Acute haemorrhagic
leukoencephalitis; Acute haemorrhagic oedema of infancy; Acute kidney
injury; Acute macular outer retinopathy; Acute motor axonal neuropathy;
Acute motor-sensory axonal neuropathy; Acute myocardial infarction; Acute respiratory distress syndrome [Note by Celia Farber: “that sounds like ‘Covid 19’.”];
Acute respiratory failure; Addison's disease; Administration site
thrombosis; Administration site vasculitis; Adrenal thrombosis; Adverse
event following immunisation; Ageusia; Agranulocytosis; Air embolism;
Alanine aminotransferase abnormal; Alanine aminotransferase increased;
Alcoholic seizure; Allergic bronchopulmonary mycosis; Allergic oedema;
Alloimmune hepatitis; Alopecia areata; Alpers disease; Alveolar
proteinosis; Ammonia abnormal; Ammonia increased; Amniotic cavity
infection; Amygdalohippocampectomy; Amyloid arthropathy; Amyloidosis;
Amyloidosis senile; Anaphylactic reaction; Anaphylactic shock;
Anaphylactic transfusion reaction; Anaphylactoid reaction; Anaphylactoid
shock; Anaphylactoid syndrome of pregnancy; Angioedema; Angiopathic
neuropathy; Ankylosing spondylitis; Anosmia; Antiacetylcholine receptor
antibody positive; Anti-actin antibody positive; Anti-aquaporin-4
antibody positive; Anti-basal ganglia antibody positive; Anti-cyclic
citrullinated peptide antibody positive; Anti-epithelial antibody
positive; Anti-erythrocyte antibody positive; Anti-exosome complex
antibody positive; Anti- GAD antibody negative; Anti-GAD antibody
positive; Anti-ganglioside antibody positive; Antigliadin antibody
positive; Anti-glomerular basement membrane antibody positive;
Anti-glomerular basement membrane disease; Anti-glycyl-tRNA synthetase
antibody positive; Anti-HLA antibody test positive; Anti-IA2 antibody
positive; Anti-insulin antibody increased; Anti-insulin antibody
positive; Anti-insulin receptor antibody increased; Anti-insulin
receptor antibody positive; Anti-interferon antibody negative;
Anti-interferon antibody positive; Anti-islet cell antibody positive;
Antimitochondrial antibody positive; Anti-muscle specific kinase
antibody positive; Anti-myelin-associated glycoprotein antibodies
positive; Anti-myelin-associated glycoprotein associated polyneuropathy;
Antimyocardial antibody positive; Anti-neuronal antibody positive;
Antineutrophil cytoplasmic antibody increased; Antineutrophil
cytoplasmic antibody positive; Anti-neutrophil cytoplasmic antibody
positive vasculitis; Anti-NMDA antibody positive; Antinuclear antibody
increased; Antinuclear antibody positive; Antiphospholipid antibodies
positive; Antiphospholipid syndrome; Anti-platelet antibody positive;
Anti-prothrombin antibody positive; Antiribosomal P antibody positive;
Anti-RNA polymerase III antibody positive; Anti-saccharomyces cerevisiae
antibody test positive; Anti-sperm antibody positive; Anti-SRP antibody
positive; Antisynthetase syndrome; Anti-thyroid antibody positive;
Anti-transglutaminase antibody increased; Anti-VGCC antibody positive;
Anti-VGKC antibody positive; Anti-vimentin antibody positive; Antiviral
prophylaxis; Antiviral treatment; Anti-zinc transporter 8 antibody
positive; Aortic embolus; Aortic thrombosis; Aortitis; Aplasia pure red
cell; Aplastic anaemia; Application site thrombosis; Application site
vasculitis; Arrhythmia; Arterial bypass occlusion; Arterial bypass
thrombosis; Arterial thrombosis; Arteriovenous fistula thrombosis;
Arteriovenous graft site stenosis; Arteriovenous graft thrombosis;
Arteritis; Arteritis
CONFIDENTIAL Page 1
FDA-CBER-2021-5683-0000083
Page 30
090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)
~
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports
[con't]
[Arteritis] coronary; Arthralgia; Arthritis; Arthritis enteropathic;
Ascites; Aseptic cavernous sinus thrombosis; Aspartate aminotransferase
abnormal; Aspartate aminotransferase increased;
Aspartate-glutamate-transporter deficiency; AST to platelet ratio index
increased; AST/ALT ratio abnormal; Asthma; Asymptomatic COVID-19;
Ataxia; Atheroembolism; Atonic seizures; Atrial thrombosis; Atrophic
thyroiditis; Atypical benign partial epilepsy; Atypical pneumonia [Note by Celia Farber: “This sounds like the original definition of Covid-19 out of Wuhan.”];
Aura; Autoantibody positive; Autoimmune anaemia; Autoimmune aplastic
anaemia; Autoimmune arthritis; Autoimmune blistering disease; Autoimmune
cholangitis; Autoimmune colitis; Autoimmune demyelinating disease;
Autoimmune dermatitis; Autoimmune disorder; Autoimmune encephalopathy;
Autoimmune endocrine disorder; Autoimmune enteropathy; Autoimmune eye
disorder; Autoimmune haemolytic anaemia; Autoimmune heparin-induced
thrombocytopenia; Autoimmune hepatitis; Autoimmune hyperlipidaemia;
Autoimmune hypothyroidism; Autoimmune inner ear disease; Autoimmune lung
disease; Autoimmune lymphoproliferative syndrome; Autoimmune
myocarditis; Autoimmune myositis; Autoimmune nephritis; Autoimmune
neuropathy; Autoimmune neutropenia; Autoimmune pancreatitis; Autoimmune
pancytopenia; Autoimmune pericarditis; Autoimmune retinopathy;
Autoimmune thyroid disorder; Autoimmune thyroiditis; Autoimmune uveitis;
Autoinflammation with infantile enterocolitis; Autoinflammatory
disease; Automatism epileptic; Autonomic nervous system imbalance;
Autonomic seizure; Axial spondyloarthritis; Axillary vein thrombosis;
Axonal and demyelinating polyneuropathy; Axonal neuropathy;
Bacterascites; Baltic myoclonic epilepsy; Band sensation; Basedow's
disease; Basilar artery thrombosis; Basophilopenia; B-cell aplasia;
Behcet's syndrome; Benign ethnic neutropenia; Benign familial neonatal
convulsions; Benign familial pemphigus; Benign rolandic epilepsy; Beta-2
glycoprotein antibody positive; Bickerstaff's encephalitis; Bile output
abnormal; Bile output decreased; Biliary ascites; Bilirubin conjugated
abnormal; Bilirubin conjugated increased; Bilirubin urine present;
Biopsy liver abnormal; Biotinidase deficiency; Birdshot
chorioretinopathy; Blood alkaline phosphatase abnormal; Blood alkaline
phosphatase increased; Blood bilirubin abnormal; Blood bilirubin
increased; Blood bilirubin unconjugated increased; Blood cholinesterase
abnormal; Blood cholinesterase decreased; Blood pressure decreased;
Blood pressure diastolic decreased; Blood pressure systolic decreased;
Blue toe syndrome; Brachiocephalic vein thrombosis; Brain stem embolism;
Brain stem thrombosis; Bromosulphthalein test abnormal; Bronchial
oedema; Bronchitis; Bronchitis mycoplasmal; Bronchitis viral;
Bronchopulmonary aspergillosis allergic; Bronchospasm; Budd- Chiari
syndrome; Bulbar palsy; Butterfly rash; C1q nephropathy; Caesarean
section; Calcium embolism; Capillaritis; Caplan's syndrome; Cardiac
amyloidosis; Cardiac arrest; Cardiac failure; Cardiac failure acute;
Cardiac sarcoidosis; Cardiac ventricular thrombosis; Cardiogenic shock;
Cardiolipin antibody positive; Cardiopulmonary failure;
Cardio-respiratory arrest; Cardio-respiratory distress; Cardiovascular
insufficiency; Carotid arterial embolus; Carotid artery thrombosis;
Cataplexy; Catheter site thrombosis; Catheter site vasculitis; Cavernous
sinus thrombosis; CDKL5 deficiency disorder; CEC syndrome; Cement
embolism; Central nervous system lupus; Central nervous system
vasculitis; Cerebellar artery thrombosis; Cerebellar embolism; Cerebral
amyloid angiopathy; Cerebral arteritis; Cerebral artery embolism;
Cerebral artery thrombosis; Cerebral gas embolism; Cerebral
microembolism; Cerebral septic infarct; Cerebral thrombosis; Cerebral
venous sinus thrombosis; Cerebral venous thrombosis; Cerebrospinal
thrombotic
CONFIDENTIAL Page 2
FDA-CBER-2021-5683-0000084
Page 31
090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)
[...]
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports
[Radiculitis]
brachial; Radiologically isolated syndrome; Rash; Rash erythematous;
Rash pruritic; Rasmussen encephalitis; Raynaud's phenomenon; Reactive
capillary endothelial proliferation; Relapsing multiple sclerosis;
Relapsing-remitting multiple sclerosis; Renal amyloidosis; Renal
arteritis; Renal artery thrombosis; Renal embolism; Renal failure; Renal
vascular thrombosis; Renal vasculitis; Renal vein embolism; Renal vein
thrombosis; Respiratory arrest; Respiratory disorder; Respiratory
distress; Respiratory failure; Respiratory paralysis; Respiratory
syncytial virus bronchiolitis; Respiratory syncytial virus bronchitis;
Retinal artery embolism; Retinal artery occlusion; Retinal artery
thrombosis; Retinal vascular thrombosis; Retinal vasculitis; Retinal
vein occlusion; Retinal vein thrombosis; Retinol binding protein
decreased; Retinopathy; Retrograde portal vein flow; Retroperitoneal
fibrosis; Reversible airways obstruction; Reynold's syndrome; Rheumatic
brain disease; Rheumatic disorder; Rheumatoid arthritis; Rheumatoid
factor increased; Rheumatoid factor positive; Rheumatoid factor
quantitative increased; Rheumatoid lung; Rheumatoid neutrophilic
dermatosis; Rheumatoid nodule; Rheumatoid nodule removal; Rheumatoid
scleritis; Rheumatoid vasculitis; Saccadic eye movement; SAPHO syndrome;
Sarcoidosis; SARS-CoV-1 test; SARS-CoV-1 test negative; SARS-CoV-1 test
positive; SARS-CoV-2 antibody test; SARS-CoV-2 antibody test negative;
SARS-CoV-2 antibody test positive; SARS-CoV-2 carrier; SARS-CoV-2
sepsis; SARS-CoV-2 test; SARS- CoV-2 test false negative; SARS-CoV-2
test false positive; SARS-CoV-2 test negative; SARS- CoV-2 test
positive; SARS-CoV-2 viraemia; Satoyoshi syndrome; Schizencephaly;
Scleritis; Sclerodactylia; Scleroderma; Scleroderma associated digital
ulcer; Scleroderma renal crisis; Scleroderma-like reaction; Secondary
amyloidosis; Secondary cerebellar degeneration; Secondary progressive
multiple sclerosis; Segmented hyalinising vasculitis; Seizure; Seizure
anoxic; Seizure cluster; Seizure like phenomena; Seizure prophylaxis;
Sensation of foreign body; Septic embolus; Septic pulmonary embolism;
Severe acute respiratory syndrome; Severe myoclonic epilepsy of infancy;
Shock; Shock symptom; Shrinking lung syndrome; Shunt thrombosis; Silent
thyroiditis; Simple partial seizures; Sjogren's syndrome; Skin
swelling; SLE arthritis; Smooth muscle antibody positive; Sneezing;
Spinal artery embolism; Spinal artery thrombosis; Splenic artery
thrombosis; Splenic embolism; Splenic thrombosis; Splenic vein
thrombosis; Spondylitis; Spondyloarthropathy; Spontaneous
heparin-induced thrombocytopenia syndrome; Status epilepticus; Stevens-Johnson
syndrome [Note by Celia Farber: “This, SJS, can result in the skin
coming off the body altogether, from the body’s attempt to rid itself of
poison.”]; Stiff
leg syndrome; Stiff person syndrome; Stillbirth; Still's disease; Stoma
site thrombosis; Stoma site vasculitis; Stress cardiomyopathy; Stridor;
Subacute cutaneous lupus erythematosus; Subacute endocarditis; Subacute
inflammatory demyelinating polyneuropathy; Subclavian artery embolism;
Subclavian artery thrombosis; Subclavian vein thrombosis; Sudden
unexplained death in epilepsy; Superior sagittal sinus thrombosis;
Susac's syndrome; Suspected COVID- 19; Swelling; Swelling face; Swelling
of eyelid; Swollen tongue; Sympathetic ophthalmia; Systemic lupus
erythematosus; Systemic lupus erythematosus disease activity index
abnormal; Systemic lupus erythematosus disease activity index decreased;
Systemic lupus erythematosus disease activity index increased; Systemic
lupus erythematosus rash; Systemic scleroderma; Systemic sclerosis
pulmonary; Tachycardia; Tachypnoea; Takayasu's arteritis; Temporal lobe
epilepsy; Terminal ileitis; Testicular autoimmunity; Throat tightness;
Thromboangiitis obliterans; Thrombocytopenia; Thrombocytopenic purpura;
Thrombophlebitis; Thrombophlebitis migrans; Thrombophlebitis
CONFIDENTIAL Page 8
FDA-CBER-2021-5683-0000090
Page 37
090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)
~
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports
[con't]
[Thrombophlebitis] neonatal; Thrombophlebitis septic; Thrombophlebitis
superficial; Thromboplastin antibody positive; Thrombosis; Thrombosis
corpora cavernosa; Thrombosis in device; Thrombosis mesenteric vessel;
Thrombotic cerebral infarction; Thrombotic microangiopathy; Thrombotic
stroke; Thrombotic thrombocytopenic purpura; Thyroid disorder; Thyroid
stimulating immunoglobulin increased; Thyroiditis; Tongue amyloidosis;
Tongue biting; Tongue oedema; Tonic clonic movements; Tonic convulsion;
Tonic posturing; Topectomy; Total bile acids increased; Toxic epidermal
necrolysis; Toxic leukoencephalopathy; Toxic oil syndrome; Tracheal
obstruction; Tracheal oedema; Tracheobronchitis; Tracheobronchitis
mycoplasmal; Tracheobronchitis viral; Transaminases abnormal;
Transaminases increased; Transfusion-related alloimmune neutropenia;
Transient epileptic amnesia; Transverse sinus thrombosis; Trigeminal
nerve paresis; Trigeminal neuralgia; Trigeminal palsy; Truncus coeliacus
thrombosis; Tuberous sclerosis complex; Tubulointerstitial nephritis
and uveitis syndrome; Tumefactive multiple sclerosis; Tumour embolism;
Tumour thrombosis; Type 1 diabetes mellitus; Type I hypersensitivity;
Type III immune complex mediated reaction; Uhthoff's phenomenon;
Ulcerative keratitis; Ultrasound liver abnormal; Umbilical cord
thrombosis; Uncinate fits; Undifferentiated connective tissue disease;
Upper airway obstruction; Urine bilirubin increased; Urobilinogen urine
decreased; Urobilinogen urine increased; Urticaria; Urticaria papular;
Urticarial vasculitis; Uterine rupture; Uveitis; Vaccination site
thrombosis; Vaccination site vasculitis; Vagus nerve paralysis;
Varicella; Varicella keratitis; Varicella post vaccine; Varicella zoster
gastritis; Varicella zoster oesophagitis; Varicella zoster pneumonia;
Varicella zoster sepsis; Varicella zoster virus infection; Vasa praevia;
Vascular graft thrombosis; Vascular pseudoaneurysm thrombosis; Vascular
purpura; Vascular stent thrombosis; Vasculitic rash; Vasculitic ulcer;
Vasculitis; Vasculitis gastrointestinal; Vasculitis necrotising; Vena
cava embolism; Vena cava thrombosis; Venous intravasation; Venous
recanalisation; Venous thrombosis; Venous thrombosis in pregnancy;
Venous thrombosis limb; Venous thrombosis neonatal; Vertebral artery
thrombosis; Vessel puncture site thrombosis; Visceral venous thrombosis;
VIth nerve paralysis; VIth nerve paresis; Vitiligo; Vocal cord
paralysis; Vocal cord paresis; Vogt-Koyanagi-Harada disease; Warm type
haemolytic anaemia; Wheezing; White nipple sign; XIth nerve paralysis;
X-ray hepatobiliary abnormal; Young's syndrome; Zika virus associated
Guillain Barre syndrome.
CONFIDENTIAL Page 9
FDA-CBER-2021-5683-0000091
Page 38
090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (GMT)
* * *
---Unless
we rebel, someday this list will be engraved on a large memorial, and
it will be framed in positive language, as an unparalleled achievement,
as the introduction to the new genetically engineered human race.
~~~
(The link to this article posted on my blog is here.)
(Follow me on Gab at @jonrappoport)
No comments:
Post a Comment